Allison Bratzel
Stock Analyst at Piper Sandler
(4.20)
# 390
Out of 5,179 analysts
61
Total ratings
53.06%
Success rate
16.03%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Allison Bratzel
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MGTX MeiraGTx Holdings | Maintains: Overweight | $30 → $26 | $7.62 | +241.21% | 2 | Mar 27, 2026 | |
| TYRA Tyra Biosciences | Maintains: Overweight | $42 → $56 | $36.29 | +54.31% | 3 | Mar 20, 2026 | |
| SRRK Scholar Rock Holding | Maintains: Overweight | $51 → $58 | $42.60 | +36.15% | 5 | Mar 4, 2026 | |
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $87 → $100 | $72.15 | +38.60% | 5 | Feb 27, 2026 | |
| TVTX Travere Therapeutics | Maintains: Neutral | $35 → $38 | $27.25 | +39.45% | 4 | Feb 6, 2026 | |
| BMRN BioMarin Pharmaceutical | Maintains: Overweight | $122 → $84 | $54.14 | +55.15% | 1 | Feb 6, 2026 | |
| INCY Incyte | Maintains: Overweight | $102 → $110 | $90.30 | +21.82% | 4 | Feb 6, 2026 | |
| AKBA Akebia Therapeutics | Maintains: Overweight | $6 → $4 | $1.34 | +198.51% | 2 | Feb 6, 2026 | |
| REPL Replimune Group | Maintains: Overweight | $13 → $14 | $7.22 | +93.91% | 3 | Feb 5, 2026 | |
| ALXO ALX Oncology Holdings | Maintains: Overweight | $3 → $4 | $2.04 | +96.08% | 1 | Feb 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $3 → $0.5 | $0.19 | +159.07% | 2 | Jan 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $820 → $930 | $691.40 | +34.51% | 15 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $112 | $102.47 | +9.30% | 1 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $140 → $115 | $19.38 | +493.40% | 1 | Mar 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $26 | $6.37 | +308.16% | 1 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $23 | $25.84 | -10.99% | 2 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $22 | $26.52 | -17.04% | 2 | Jul 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 | $0.68 | +492.07% | 2 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $8 → $20 | $7.11 | +181.29% | 4 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $20 | $3.27 | +511.62% | 1 | Oct 13, 2023 |
MeiraGTx Holdings
Mar 27, 2026
Maintains: Overweight
Price Target: $30 → $26
Current: $7.62
Upside: +241.21%
Tyra Biosciences
Mar 20, 2026
Maintains: Overweight
Price Target: $42 → $56
Current: $36.29
Upside: +54.31%
Scholar Rock Holding
Mar 4, 2026
Maintains: Overweight
Price Target: $51 → $58
Current: $42.60
Upside: +36.15%
Ionis Pharmaceuticals
Feb 27, 2026
Maintains: Overweight
Price Target: $87 → $100
Current: $72.15
Upside: +38.60%
Travere Therapeutics
Feb 6, 2026
Maintains: Neutral
Price Target: $35 → $38
Current: $27.25
Upside: +39.45%
BioMarin Pharmaceutical
Feb 6, 2026
Maintains: Overweight
Price Target: $122 → $84
Current: $54.14
Upside: +55.15%
Incyte
Feb 6, 2026
Maintains: Overweight
Price Target: $102 → $110
Current: $90.30
Upside: +21.82%
Akebia Therapeutics
Feb 6, 2026
Maintains: Overweight
Price Target: $6 → $4
Current: $1.34
Upside: +198.51%
Replimune Group
Feb 5, 2026
Maintains: Overweight
Price Target: $13 → $14
Current: $7.22
Upside: +93.91%
ALX Oncology Holdings
Feb 5, 2026
Maintains: Overweight
Price Target: $3 → $4
Current: $2.04
Upside: +96.08%
Jan 26, 2026
Downgrades: Neutral
Price Target: $3 → $0.5
Current: $0.19
Upside: +159.07%
Nov 4, 2025
Maintains: Overweight
Price Target: $820 → $930
Current: $691.40
Upside: +34.51%
Jul 29, 2025
Maintains: Overweight
Price Target: $70 → $112
Current: $102.47
Upside: +9.30%
Mar 17, 2025
Maintains: Overweight
Price Target: $140 → $115
Current: $19.38
Upside: +493.40%
Feb 18, 2025
Initiates: Overweight
Price Target: $26
Current: $6.37
Upside: +308.16%
Nov 14, 2024
Maintains: Neutral
Price Target: $15 → $23
Current: $25.84
Upside: -10.99%
Jul 10, 2024
Maintains: Overweight
Price Target: $20 → $22
Current: $26.52
Upside: -17.04%
Mar 26, 2024
Maintains: Neutral
Price Target: $4
Current: $0.68
Upside: +492.07%
Mar 14, 2024
Upgrades: Overweight
Price Target: $8 → $20
Current: $7.11
Upside: +181.29%
Oct 13, 2023
Assumes: Overweight
Price Target: $20
Current: $3.27
Upside: +511.62%